{
    "cancelStatus": "0",
    "licStatus": "1",
    "cancelDate": null,
    "cancelReason": [],
    "otherCancelReason": "",
    "licid": "60001025",
    "licUnit": "1",
    "validDate": "2026-10-13 00:00:00.000",
    "issueDate": "2024-10-28 00:00:00.000",
    "oriIssueDate": "2016-10-13",
    "licKind": "04",
    "oldLicid": null,
    "certNo": "DHA06000102500",
    "prodNameC": "吉舒達注射劑",
    "prodNameE": "Keytruda Injection",
    "indicationsName": [
        "1.黑色素細胞瘤：\n治療無法切除或轉移性黑色素瘤病人。\n作為輔助性療法治療患有第IIB或IIC期黑色素瘤並已進行完全切除的成人與12歲以上兒童病人。\n作為輔助性療法治療侵犯至淋巴結並已進行完全切除的黑色素瘤病人。\n2.非小細胞肺癌：\n單獨使用，用於第一線治療經確效之試驗檢測出腫瘤表現PD-L1 (tumor proportion score (TPS) ≥ 1%) 且不具有EGFR或ALK腫瘤基因異常的局部晚期或轉移性非小細胞肺癌病人。\n單獨使用，治療接受含鉑化學治療後疾病惡化且經確效之試驗檢測出腫瘤表現PD-L1 (tumor proportion score ≥ 1%) 的晚期非小細胞肺癌病人，病人若具有EGFR或ALK腫瘤基因異常者，則須經EGFR或ALK抑制劑治療後出現疾病惡化現象。\n與pemetrexed及含鉑化學療法併用，做為轉移性，不具有EGFR或ALK腫瘤基因異常之非鱗狀非小細胞肺癌的第一線治療藥物。\n與carboplatin及paclitaxel或nab-paclitaxel併用，做為轉移性鱗狀非小細胞肺癌的第一線治療藥物。與含cisplatin化療藥物併用，做為可切除的非小細胞肺癌病人(腫瘤大小>4公分，淋巴結分期≤N2)的前導性治療用藥(neoadjuvant therapy)，並於手術後繼續單獨使用做為輔助治療用藥(adjuvant therapy)。\n單獨使用，用於已完全切除且術後接受含鉑藥物化學治療之非小細胞肺癌(NSCLC)且具高復發風險病人的輔助治療(adjuvant therapy)。\n3.惡性胸膜間皮瘤：\n與pemetrexed及含鉑化學療法併用，做為無法切除之晚期或轉移性惡性胸膜間皮瘤(MPM, malignant pleural mesothelioma)成人病人的第一線治療藥物。\n4.典型何杰金氏淋巴瘤：\n治療罹患復發或頑固性典型何杰金氏淋巴瘤的成人病人。\n治療罹患頑固性或先前至少已接受兩線治療仍復發之典型何杰金氏淋巴瘤的兒童病人。\n5.頭頸部鱗狀細胞癌：\n與含鉑化學療法及fluorouracil(FU)併用，做為轉移性或無法切除之復發性頭頸部鱗狀細胞癌(HNSCC)病人的第一線治療藥物。\n單獨使用，治療患有轉移性或無法切除之復發性頭頸部鱗狀細胞癌，且經確效之試驗檢測出腫瘤有PD-L1表現[綜合陽性分數(CPS) ≥1]之病人的第一線治療藥物。\n單獨使用，治療在使用含鉑化學治療期間或治療後出現疾病惡化的復發或轉移性頭頸部鱗狀細胞癌，且經確效之試驗檢測出腫瘤有PD-L1表現[綜合陽性分數(CPS) ≥1]的病人。\n6.泌尿道上皮癌：\n與enfortumab vedotin 併用，治療局部晚期或轉移性泌尿道上皮癌的成人病人。\n單獨使用，治療接受含鉑化學治療期間或治療後出現疾病惡化現象，或於使用含鉑化學療法進行前導性或輔助性治療後12個月內出現疾病惡化現象的局部晚期或轉移性泌尿道上皮癌病人。\n單獨使用，治療不適合接受任何含鉑化學療法的局部晚期或轉移性泌尿道上皮癌病人。\n單獨使用，治療有原位癌(CIS)，有或沒有乳頭狀腫瘤，且不適合進行或決定不進行膀胱切除術的卡介苗(BCG)無反應性、高危險、非肌肉侵犯性膀胱癌(NMIBC)病人。\n7.胃癌：\n與fluoropyrimidine及含鉑化學療法併用，做為局部晚期無法切除或轉移性之HER2陰性胃腺癌(adenocarcinoma)或胃食道接合部(gastroesophageal junction,GEJ)腺癌成年病人的第一線治療藥物。\n與trastuzumab、fluoropyrimidine及含鉑化學療法併用，做為經確效之試驗檢測出腫瘤有PD-L1表現[綜合陽性分數(CPS) ≥1]之局部晚期無法切除或轉移性之HER2陽性胃腺癌或胃食道接合部(GEJ)腺癌病人的第一線治療藥物。\n8.原發性縱膈腔B細胞淋巴瘤：\n治療罹患頑固性或先前至少已接受兩種治療仍復發之原發性縱膈腔B細胞淋巴瘤的成人及兒童病人。\n9.高微衛星不穩定性(microsatellite instability high; MSI-H)或錯誤配對修復功能不足性(mismatch repair deficient; dMMR)癌症：\n治療患有無法切除或轉移性高微衛星不穩定性(MSI-H)或錯誤配對修復功能不足(dMMR)之下列癌症的成人病人。\n使用fluoropyrimidine, oxaliplatin及irinotecan治療後出現惡化現象的大腸直腸癌，或於先前治療後出現惡化現象且無任何其他適當之替代治療選擇的實體腫瘤。\n10.高微衛星不穩定性或錯誤配對修復功能不足性大腸直腸癌：\n做為無法切除或轉移性高微衛星不穩定性(MSI-H)或錯誤配對修復功能不足(dMMR)大腸直腸癌(CRC)病人的第一線治療藥物。\n11.肝細胞癌：\n治療先前經sorafenib治療的肝細胞癌 (HCC)病人。\n12.膽管癌(Biliary Tract Carcinoma)：\n與gemcitabine 及cisplatin 併用，治療患有局部晚期無法切除或轉移性之膽管癌（BTC）的病人。\n13.子宮頸癌：\n與同步化學放射療法併用，治療高復發風險之局部晚期子宮頸癌病人。\n與化學療法併用，合併或不合併bevacizumab，治療經確效之試驗檢測出腫瘤有PD-L1表現(CPS>=1)的持續性、復發或轉移性子宮頸癌病人。\n單獨使用，治療經確效之試驗檢測出腫瘤有PD-L1表現 (CPS≥1)，且在接受化學治療期間或治療後出現疾病惡化現 象的復發或轉移性子宮頸癌病人。\n14.腎細胞癌：\n與axitinib併用，做為晚期腎細胞癌病人的第一線治療藥物。\n與lenvatinib併用，做為晚期腎細胞癌病人的第一線治療藥物。做為中高或高復發風險腎細胞癌成人病人在腎切除術後或腎臟及轉移病灶切除後的輔助治療。\n15.子宮內膜癌：\n與carboplatin 及paclitaxel 併用，隨後作為單一療法，治療原發性晚期或復發性子宮內膜癌病人。\n與lenvatinib併用適用於曾經以任何形式接受過全身性治療後疾病惡化，且不適合根治手術或放射治療之晚期子宮內膜癌病人。\n16.食道癌：\n與含鉑及fluoropyrimidine之化學療法併用，做為局部晚期無法切除或轉移性食道癌或胃食道接合部癌病人的第一線治療藥物。\n作為單一療法，治療患有復發性局部晚期或轉移性食道鱗狀細胞癌，經確效之試驗檢測出腫瘤有PD-L1表現(綜合陽性分數[CPS]≥10)，且先前曾接受一種(含)以上全身性治療，於治療時或治療後發生疾病惡化的病人。\n17.三陰性乳癌(Triple Negative Breast Cancer)：\n與化學療法併用，做為高風險早期三陰性乳癌 (TNBC) 病人的前導性治療用藥，並於手術後繼續單獨使用做為輔助治療用藥。\n與化學療法併用，治療局部復發性無法切除或轉移性之三陰性乳癌(TNBC)，且經確效之試驗檢測出腫瘤有PD-L1表現(綜合陽性分數[CPS]≥10)病人。\n18.高腫瘤突變負荷量(Tumor Mutational Burden-High; TMB-H)癌症：\n治療患有無法切除或轉移性、經確效之試驗檢測出高腫瘤突變負荷量(tumor mutation burden high [TMB-H]) [≥10 mutations \/ megabase (mut\/Mb)]、於先前治療後出現惡化現象且無任何其他適當替代治療選擇之實體腫瘤的成人病人。"
    ],
    "does": "2270",
    "packageUnit": [
        {
            "packageSpec": "100mg\/4mL",
            "packageUnit": "1A"
        }
    ],
    "medMCode": "05",
    "maMedCode": "",
    "medDCode": null,
    "mainCategory": null,
    "drBaseId": "83287F53-DDFA-4C4B-99E6-500F165CA17F",
    "subCategory": [],
    "ingredientsDesc": [
        "Pembrolizumab"
    ],
    "restraintItemsCode": [
        "02 輸 入",
        "07 新藥監視"
    ],
    "applicantName": "美商默沙東藥廠股份有限公司台灣分公司",
    "applicantAddr": "台北市信義區信義路五段106號12樓",
    "medClass": null,
    "efficacy": " ",
    "mdFormat": null,
    "productAnnotation": "",
    "mdKind": [],
    "monitorDate": "2021-10-13",
    "licidNew": null,
    "licidOld": null,
    "factoryDtoList": [
        {
            "id": "9750F0A0-C031-4621-B7A7-79812586F7D2",
            "factoryCode": "1",
            "factoryName": "MSD International GmbH T\/A MSD Ireland (Carlow)",
            "factoryAddr": "DUBLIN RD., CARLOW, COUNTY CARLOW, IRELAND",
            "factoryCompanyAddr": "",
            "countryCode": "IE",
            "processCode": [],
            "processCodeStr": null,
            "factoryKind": "M",
            "factoryNo": "FIE0099000",
            "factoryInfo": null,
            "qsd": null,
            "qsdList": [],
            "factoryMadeIn": null
        },
        {
            "id": "C9204DB4-F35F-4BE4-B758-8B067A370B91",
            "factoryCode": "1",
            "factoryName": "MSD International GmbH (Singapore Branch)",
            "factoryAddr": "60, TUAS WEST DRIVE, SINGAPORE, 638413",
            "factoryCompanyAddr": null,
            "countryCode": "SG",
            "processCode": [
                {
                    "value": "66",
                    "name": "成品製造廠"
                }
            ],
            "processCodeStr": "66;成品製造廠",
            "factoryKind": "M",
            "factoryNo": "FSG0012000",
            "factoryInfo": null,
            "qsd": null,
            "qsdList": [],
            "factoryMadeIn": null
        },
        {
            "id": "82A4076A-726E-4FC9-8A79-4F46F0726F8A",
            "factoryCode": "2",
            "factoryName": "Organon Heist bv",
            "factoryAddr": "Industriepark 30, 2220 Heist-op-den-Berg, Belgium",
            "factoryCompanyAddr": "",
            "countryCode": "BE",
            "processCode": [
                {
                    "value": "02",
                    "name": "包裝"
                }
            ],
            "processCodeStr": "02;包裝",
            "factoryKind": "M",
            "factoryNo": "FBE0122000",
            "factoryInfo": null,
            "qsd": null,
            "qsdList": [],
            "factoryMadeIn": null
        },
        {
            "id": "45AC7828-A893-4C63-AF21-ED62696C426B",
            "factoryCode": "2",
            "factoryName": "BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG",
            "factoryAddr": "BIRKENDORFER STRASSE 65, 88397 BIBERACH AN DER RISS, GERMANY",
            "factoryCompanyAddr": null,
            "countryCode": "DE",
            "processCode": [
                {
                    "value": "1K",
                    "name": "原料藥製造廠"
                }
            ],
            "processCodeStr": "1K;原料藥製造廠",
            "factoryKind": "M",
            "factoryNo": "FDE0215200",
            "factoryInfo": null,
            "qsd": null,
            "qsdList": [],
            "factoryMadeIn": null
        },
        {
            "id": "CAF1963D-F60F-4862-B6A6-6E98775BBAC2",
            "factoryCode": "2",
            "factoryName": "MSD International GmbH",
            "factoryAddr": "Drynam Road, Swords, Dublin, K67 P263 Ireland",
            "factoryCompanyAddr": "",
            "countryCode": "IE",
            "processCode": [
                {
                    "value": "1K",
                    "name": "原料藥製造廠"
                }
            ],
            "processCodeStr": "1K;原料藥製造廠",
            "factoryKind": "M",
            "factoryNo": "FIE0156000",
            "factoryInfo": null,
            "qsd": null,
            "qsdList": [],
            "factoryMadeIn": null
        },
        {
            "id": "7599630E-905D-4E0E-9338-4EEBAD2B0CC3",
            "factoryCode": "2",
            "factoryName": "MSD INTERNATIONAL GMBH  (SINGAPORE BRANCH)",
            "factoryAddr": "70 TUAS WEST DRIVE, SINGAPORE 638414",
            "factoryCompanyAddr": "",
            "countryCode": "SG",
            "processCode": [
                {
                    "value": "1A",
                    "name": "二級包裝廠"
                }
            ],
            "processCodeStr": "1A;二級包裝廠",
            "factoryKind": "M",
            "factoryNo": "FSG0012100",
            "factoryInfo": null,
            "qsd": null,
            "qsdList": [],
            "factoryMadeIn": null
        },
        {
            "id": "49148C09-14E0-4F89-9A3E-405A515C6A88",
            "factoryCode": "2",
            "factoryName": "ASTRAZENECA PHARMACEUTICALS LP",
            "factoryAddr": "633 RESEARCH COURT, FREDERICK, MARYLAND 21703, USA",
            "factoryCompanyAddr": "",
            "countryCode": "US",
            "processCode": [
                {
                    "value": "1K",
                    "name": "原料藥製造廠"
                }
            ],
            "processCodeStr": "1K;原料藥製造廠",
            "factoryKind": "M",
            "factoryNo": "FUS0980000",
            "factoryInfo": null,
            "qsd": null,
            "qsdList": [],
            "factoryMadeIn": null
        }
    ],
    "ingredientsDtoList": [
        {
            "ingredientsKind": "1",
            "ingredientsCode": "1013005400",
            "ingredientsName": "Pembrolizumab",
            "ingredientsDesc": "Pembrolizumab",
            "concentDesc": "",
            "concent": "100.000000",
            "concentUnit": "001",
            "seq": "1",
            "prescription_seq": "1",
            "prescription_Kind": "1"
        }
    ],
    "authDtoList": [],
    "iomDtoList": [],
    "changeDtoList": [],
    "atcList": [
        {
            "isMain": "1",
            "atcCode": "L01FF02"
        }
    ],
    "licBaseId": "B7EEF078-62DD-4FA3-9FC5-66AAA2BB860B"
}